Deanne Minniecon, Group Executive, Aboriginal and Torres Strait Islander Engagement, has been appointed as an聽Adjunct Associate Professor in the School of Public Health at the University of Queensland (UQ).

This appointment is a wonderful recognition of Deanne’s more than 30-year career in Aboriginal and Torres Strait Islander health and the significant contributions she has made across community, policy, leadership, research, teaching, and learning. It also acknowledges the valuable work Deanne has already undertaken with UQ and provides an opportunity for her to continue contributing to research, mentoring, teaching, and workforce development. 

For 芒果直播, this appointment creates opportunities to strengthen partnerships across the university sector and contribute to shaping future research, education, and workforce development. It helps ensure that Aboriginal and Torres Strait Islander perspectives, knowledge, and lived experiences continue to inform health research, education, and practice, while supporting the development of the next generation of health professionals and researchers.

This is a particularly meaningful appointment for Deanne, as it is her second Adjunct Associate Professor role alongside her existing position at Queensland University of Technology (QUT). It will enable her to further connect her work across community, policy and practice with the academic sector, helping to translate knowledge into improved outcomes for Aboriginal and Torres Strait Islander peoples.

Congratulations to Deanne on your well-deserved appointment.

芒果直播, Australian聽Unity聽and Deakin University join forces to build a more complete picture of life with diabetes.聽

For the first time, the Australian Unity Wellbeing Index will be used to build the most complete picture yet of how diabetes affects Australian鈥檚 lives beyond clinical outcomes and health system costs, thanks to a partnership聽between聽芒果直播,聽Deakin University, and the Australian Unity Support Foundation.聽聽

The partnership will explore a growing recognition that the true impact of diabetes is not fully captured by hospital visits, treatment costs, or clinical measures alone. 

Current estimates place the financial cost of diabetes to the health system at $9 billion year, but this measure just captures clinical settings.  

International studies indicate that at least one quarter of the impact happens outside of the health system, meaning the real impact to Australians living with diabetes may be vastly under-represented.  

Diabetes impacts beyond clinical management to include mental wellbeing, financial security, personal relationships, community connection and people鈥檚 ability to shape their own lives. 

And, with more than two million Australians living with both diagnosed and undiagnosed diabetes, the effects extend to many corners of life.   

Now, the nation鈥檚 leading wellbeing index will produce the most comprehensive snapshot yet of diabetes鈥� wider impact, aiming to shift the conversation towards recognising whole-of-life impact rather than solely relying on health system interactions.   

The Australian Unity Wellbeing Index is a fixture on the national policy-making calendar, with this partnership bringing together the Australian Unity Support Foundation, 芒果直播, and Deakin University to deliver a landmark research project focused on the lived experience of diabetes.   

The partnership was formally launched at聽a聽forum in Melbourne聽today (Wednesday, 12 August), bringing together health leaders, researchers and people living with diabetes to examine what it means to live well with聽diabetes, where聽new聽research is聽needed聽and聽what health systems, services and policymakers can do to better support聽care and management outside of clinical settings.聽聽

The launch comes ahead of next weeks鈥� International Diabetes Federation Western Pacific Region Congress in Melbourne, where researchers from Deakin University, the Australian Unity Support Foundation and 芒果直播 will introduce the initiative to an international health, research and lived-experience audience. 

Kelly Bayer Rosmarin, Group Managing Director and Chief Executive Officer of Australian Unity, said the partnership would help build a more complete understanding of whether Australia鈥檚 health and support systems were working for people living with diabetes.  

鈥淲ellbeing isn鈥檛 a soft add-on to healthcare. It is one of the clearest ways we can understand whether care is improving people鈥檚 lives ,鈥� Ms Bayer Rosmarin said.  

鈥淔or more than twenty-five years Australian Unity has studied what helps Australians live well. By applying that evidence to the lived experience of people with diabetes, we can build a clearer picture of what people need and help shape better policy, services and support.鈥�  

Justine Cain, Group CEO, 芒果直播, said the partnership would give greater visibility to the unseen impact of living with diabetes.  

鈥淐linical measures such as glucose monitoring remain essential, but can鈥檛 tell us about the impact diabetes has on daily life,鈥� Ms Cain said.  

鈥淒iabetes care cannot be judged by clinical outcomes alone. If clinicians focus exclusively on HbA1c, weight or other clinical indicators without considering how people feel, function and live with their condition, they are not providing truly person-centred care. 

鈥淧eople living with diabetes can make up to 180 extra decisions a day, and they tell us the impact extends to their mental health, relationships, finances, work and sense of independence. This partnership puts those lived experiences at the centre of the evidence to help us better understand the real cost, and where change is needed,鈥� she said.  

Dr Kate Lycett of Deakin University said rigorous research would provide a pathway for lived experience to inform meaningful policy and practice.  

鈥淐ombining established wellbeing measures with the experiences of people living with diabetes will give us a much richer understanding of the condition鈥檚 impact,鈥� Dr Lycett said.  

鈥淒eakin鈥檚 role is to ensure the partnership is underpinned by rigorous, evidence-based research that can translate lived experience into meaningful improvements in policy, programs and services.鈥�  

People living with diabetes will contribute throughout the development of the research, including through 芒果直播鈥檚 Blue Circle Collective, to ensure the questions asked and the insights generated reflect real-world experiences and priorities.  

The partners intend for the research to contribute to future policy submissions, service design, advocacy and program development, with further details about the research methodology and timing to be announced as the program progresses. 

A new partnership between 芒果直播 and the Medibank Better Health Research Hub will support Monash University to develop a primary care model to better detect and prevent type 2 diabetes in women living with polyendocrine metabolic ovarian syndrome (PMOS). 

PMOS, formerly known as polycystic ovarian syndrome (PCOS), is a hormonal and metabolic condition affecting 1 in 8 women in Australia, with impacts on weight, mental health and wellbeing, skin and the reproductive system.  

Despite women living with the condition having a significantly higher risk of developing type 2 diabetes, they often face challenges in diagnosis and prevention options in primary care settings. 

The project will pilot a new screening and management tool for women living with PMOS that integrates into existing general practice workflows, aiming to streamline identification, referrals to specialists and prevention programs including the Get Healthy Service administered by 芒果直播, as well as shared decision-making, into existing approaches to care.  

芒果直播 Group CEO Justine Cain said the project highlighted a significant gap in women鈥檚 health research, with PMOS a well-known risk factor that could help identify and prevent or delay type 2 diabetes.  

鈥淲omen living with PMOS are four times more likely to develop diabetes over their lifetime. That鈥檚 a statistic we鈥檙e hoping to change through the development of better screening and prevention tools,鈥� Ms Cain said.  

鈥淧MOS, like diabetes, can be hard to diagnose, and affects hormonal balance for up to one in eight women. 

鈥淗istoric and ongoing research gaps in women鈥檚 health further complicate this challenge, meaning many women who are diagnosed with PMOS aren鈥檛 informed about their elevated diabetes risk, which is a real concern.  

鈥溍⒐辈� is excited to partner with Medibank and Monash University to deliver research that will drive real change in women鈥檚 health outcomes.鈥� 

Dr Shona Sundaraj, Group Medical Director at Medibank said the research is an opportunity to improve health outcomes for women. 

鈥淭oo many women living with PMOS are not informed about their elevated risk of type 2 diabetes until much later in their healthcare journey,鈥� Dr Sundaraj said. 

鈥淏y better supporting GPs to identify and manage this risk in their patients, we have an opportunity to intervene earlier and improve the long-term health outcomes for our patients.  

鈥淔or the women themselves, it鈥檚 about giving them the knowledge and tools to empower them in their health and healthcare.鈥� 

Monash University Centre for Health Research and Implementation lead investigator Dr Stephanie Cowan said the award would help advance primary care and screening tools that better cater for women鈥檚 health needs.  

鈥淭his funding gives us the opportunity to move beyond knowing what good care looks like for women with PMOS and actually build the systems and tools that make it possible in everyday practice,鈥� Dr Cowan said.  

鈥淏y embedding guideline-recommended screening and lifestyle support directly into GP workflows, this project will ensure that the millions of Australian women with PMOS who face a four-fold higher risk of type 2 diabetes are identified early and connected to care before that risk becomes reality.鈥� 

The project will start in July 2026 and operate until June 2028.  

A total of $230,000 will be invested, with contributions from 芒果直播 and the Medibank Better Health Research Hub to support this important research led by Monash University. 

New report shows free Shane Warne Legacy Health Checks are changing lives

Latrobe Health Services, a not-for-profit member-owned health fund, has partnered with the Shane Warne Legacy since 2023 and is proud to be the Legacy’s Founding Partner, supporting the delivery of free health checks to communities across Australia.

Together with Health Partner, 芒果直播, the partnership has supported Shane Warne Legacy to deliver free health checks across the country, raising awareness of cardiovascular and type 2 diabetes risks.

The Shane Warne Legacy Health Check program has brought more than 490,000 free, accessible health checks into places where people already go such as major sporting events, Priceline Pharmacies, workplaces and community events, making early action in the prevention of cardiovascular disease and type 2 diabetes easier.

Recent research commissioned by Latrobe Health, in collaboration with IPSOS, surveyed over 1,224 people aged 18 to 65 from diverse demographics and metro and regional locations, comparing those who have undergone health checks with those who have not.

The findings reveal critical insights into health literacy, motivations and behaviours surrounding the health checks.

Results of the research show:

• 85% of health check participants took action as a result of their health check

• 78% of health check participants felt more able to take proactive steps to prevent serious health issues (84% for those participants with a risk factor)

• 52% of health check participants believe the health check improved their health, with regional participants (60%) more likely to agree with this statement

• 39% of health check participants felt the health check was the single most important thing they had done for their health in 12 months, jumping to 43% for regional Australians and 45% for those with a risk factor

• 20% of health check participants booked an appointment with a healthcare provider

• 94% of participants would recommend the health check to others

Additionally, the research indicates that the vast majority (85%) of Shane Warne Legacy Health Check
participants went on to do something good for their health, from improving diet and increasing exercise to seeking medical advice. For those at higher risk, that number is significantly higher at 91%, with many taking more proactive steps such as booking follow-up appointments with their doctor or researching their health further.

As a not-for-profit health fund, Latrobe Health Services is all in on improving inclusivity and equity in healthcare, especially for those in rural and regional areas. Regional participants, in particular, valued the Shane Warne Legacy Health Checks as a practical solution where health services can be harder to reach.

The primary motivator for taking a health check was it being free, followed by curiosity about personal
health, particularly in regional areas where access to health information and services is often limited.
Regional participants demonstrated proactivity post-check, notably in improving diet and scheduling
follow-up health appointments.

鈥淭his research confirms what we鈥檝e always believed: when barriers to health screening are removed, people engage with the screening and act on their results. Shane Warne Legacy Health Checks are helping more Australians understand their health, act on potential risks sooner and take meaningful steps towards a healthier future,鈥� said Ian Whitehead, CEO of Latrobe Health Services.

鈥淭he outcomes for people taking advantage of the free health checks are clear 鈥� they only take five minutes and can spark positive changes in your life,鈥� added Whitehead.

The checks, conducted on SiSU Health Stations, are non-invasive, fast, and free. They include
measurements of blood pressure, cholesterol, body mass index (BMI), diabetes risk, and estimated heart age – crucial indicators of cardiometabolic health.

鈥淭his research confirms what we鈥檝e seen on the ground since day one. People don鈥檛 avoid their health
because they don鈥檛 care, they avoid it because it鈥檚 hard to access and harder to understand. Strip away those barriers and give people clear answers, and they act. That鈥檚 the whole idea behind Shane Warne Legacy, and these results tell us we鈥檙e just getting started,鈥� stated Rob Tassie, CEO of Shane Warne Legacy.

鈥淎lmost half a million health checks and counting. But the number that matters most to me is 85 per
cent, that鈥檚 how many people did something about their health as a result. That鈥檚 real impact, and it鈥檚
why we鈥檒l keep pushing to get these checks in front of more Australians,鈥� added Tassie.

鈥淪hane Warne Legacy Health Checks are a powerful tool in the prevention of type 2 diabetes, and this
report demonstrates the powerful impact they are having in the community,鈥� said Justine Cain, Group
CEO of 芒果直播.

The Shane Warne Legacy Health Checks exemplify the critical importance of bringing healthcare to
where people are. With the right technology and partnerships, lives can be changed in mere minutes.

Thanks to support from Latrobe Health Services and 芒果直播, these life-changing health
checks are available for free across Australia, marking a new model for nationwide health intervention.

The Therapeutic Goods Administration has聽updated聽GLP-1 RA聽product warnings聽because of their聽potential聽to cause a rare but severe eye disorder.聽

The glucagon-like peptide-1 receptor agonist (GLP-1 RAs) class of medicines are used to primarily treat type 2 diabetes and obesity. 

Emerging evidence suggests that semaglutide may be associated with a small increase in risk, although the absolute risk remains low.  

Seek urgent medical attention if you experience sudden loss of vision. 

The eye disorder, non-arteritic anterior ischaemic optic neuropathy, is a rare condition that may result in permanent visual impairment, including blindness, and no treatment has been shown to improve visual acuity outcomes.

The GLP-1 RA class of medicines currently marketed in Australia are:

• Trulicity – (dulaglutide)
• Ozempic – (semaglutide)
• Wegovy – (semaglutide)
• Mounjaro – (tirzepatide)*
• Saxenda – (liraglutide)

* Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA.

Please follow this link for further information: <

The safety of people living with diabetes must always come first. For many Australians, technologies such as insulin pumps and continuous glucose monitors are essential tools that help prevent dangerous high and low blood glucose levels, reduce the daily burden of living with diabetes and improve long-term health outcomes. For some individuals they can be life-changing or even life-saving.

People living with diabetes need access to balanced, evidence-based information so they can make informed decisions in consultation with their healthcare professionals. When public discussions focus solely on potential risks without also explaining proven benefits, there is a risk that individuals may lose confidence in technologies recommended by their healthcare team that could improve their health outcomes. Informed decisions are best made when people understand both the risks and benefits.

People living with diabetes deserve safe, well-regulated technologies, robust oversight when issues arise, and public conversations that accurately reflect both the risks and the substantial benefits of these important medical devices.

芒果直播 supports rigorous regulation, monitoring and oversight of all medical devices used in Australia. An individual or a healthcare professional can report adverse events to the Therapeutic Goods Administration (TGA). Any adverse event involving a medical device is concerning and should be thoroughly investigated.

People living with diabetes can benefit greatly from diabetes technologies and rightly expect that those available in Australia meet appropriate quality, safety and regulatory standards, and that regulators, manufacturers and healthcare professionals work together to continuously improve patient safety.

Diabetes affects around two million Australians and can cause serious complications including cardiovascular disease, stroke, kidney disease, vision loss and amputation. Many of these complications can be delayed or prevented through person-centred diabetes management, appropriate healthcare and access to evidence-based treatments and technologies.

There is a substantial body of Australian and international evidence showing that diabetes technologies, including continuous glucose monitors, insulin pumps and automated insulin delivery systems, can improve health outcomes, reduce serious complications, help keep people out of hospital and improve quality of life. For many Australians, these technologies have been transformational, helping people achieve better glucose management, reduce the daily burden of diabetes and live longer, healthier lives.

Diabetes technologies are not immune from potential failure. For this reason, it is essential that people using them have an individualised back-up plan in place and know what steps to take if a device is not working as expected. That plan should be developed with a diabetes care team.

Anyone experiencing difficulties with their diabetes technology should contact the device manufacturer, and seek advice from their healthcare professional, as soon as possible.

Public discussion of medical technologies plays an important role in maintaining confidence in our health system and ensuring that safety concerns are identified and addressed. It is equally important that these discussions reflect the full picture. Alongside legitimate concerns about adverse events, Australians should also understand the significant benefits that these technologies provide to many people living with diabetes every day.

As the national peak body representing Australians living with diabetes, 芒果直播’s advocacy and policy positions are formed independently and are informed by evidence, expert clinical advice and the lived experience of people living with diabetes. Everything we do is guided by one priority: improving the health, safety and wellbeing of the community we serve.

Informed choice matters. Safety matters. Evidence matters.

Justine Cain
Group Chief Executive Officer
芒果直播

For more information about evidence based clinical guidelines for diabetes   for Medical device technology for the management of type 1 diabetes have been developed by the Living Evidence for Diabetes Consortium, which is a collaboration between the Australian Diabetes Society (ADS), 芒果直播 (DA), the Australian Diabetes Educators Association (ADEA) and the Australasian Paediatric Endocrine Group (APEG), with representation from the Royal Australian College of General Practitioners (RACGP), the Australian Government Department of Health and Cochrane Australia.

A major funding boost will expand digital health solutions for complex care in the Northern Territory (NT), thanks to a joint investment from 芒果直播 and Lilly Australia, in partnership with Menzies School of Health Research (Menzies).  

The grant of $680,000 will enable Menzies to expand its innovative work to address leading health complications for Territorians, including diabetes, cardiovascular and kidney disease.  

It will also see investment in Aboriginal and Torres Strait Islander workforce capacity, through the establishment of two identified research positions based at Menzies.  

In partnership with government, community-controlled and private health services across the NT, Menzies has built a clinical information system that integrates and synthesises health data from previously siloed medical records. The groundbreaking system, known as  is already used by more than 1500 clinicians to support patients in the NT.  

This new collaboration will enable Menzies to strengthen TKC鈥檚 capabilities, providing technology-enabled models of care that enhance co-ordination of healthcare. This will be particularly valuable for people living with multiple chronic conditions, where a more integrated approach will support better health outcomes.  

芒果直播鈥檚 Group CEO Justine Cain said the investment reflected a deep commitment to improving the lives of Aboriginal and Torres Strait Islander communities and to delivering local, culturally safe services.  

鈥淜idney health is key to ongoing diabetes care and is a key indicator of health and complication outcomes. Diabetes shouldn鈥檛 cost your kidneys.鈥� Ms Cain said.  

鈥淚t is completely unacceptable that Aboriginal and Torres Strait Islander communities continue to be disproportionally impacted by diabetes. 芒果直播 is committed to real change that will support healthier futures.  

鈥淲e鈥檙e proud to partner with Lilly Australia and Menzies School of Health Research to directly support communities where kidney, diabetes and heart healthcare is greatly needed.鈥� 

Manny Simons, General Manager of Eli Lilly (Lilly) Australia said, 鈥淣o one organisation can solve the complex challenges of diabetes, kidney and cardiovascular disease.鈥� 

鈥淎t Lilly, we are committed to supporting initiatives that address health inequities and improve access to more connected, coordinated care. This investment reflects our belief that locally led, evidence-based solutions can improve health outcomes and inform future models of care across Australia.鈥� 

Menzies School of Health Research鈥檚 Director, Professor Alan Cass said, 鈥渢oo many Aboriginal and Torres Strait Islander people in the Northern Territory are impacted by diabetes, kidney and heart disease.鈥� 

鈥淭KC has brought together research, health service, government and community partners to develop a clinical decision support and data sharing platform to provide the best care to people with complex chronic disease. Together we are working to Close the Gap and reduce the ever-increasing number of people needing dialysis across remote Australia,鈥� he said. 

Lilly Australia will contribute $430,000 and 芒果直播 will contribute $250,000 to this partnership.

This National Diabetes Week, we’re looking ahead to a landmark moment for our community, one that will see the voices, wishes, and lived experiences of Australians with diabetes shared on a truly global stage.

In August 2026, Melbourne will host one of the most significant diabetes meetings ever held in the Western Pacific Region: The (IDF-WPR Congress 2026).

What is the IDF鈥慦PR Congress, and why is 芒果直播 co-hosting?

The IDF-WPR Congress 2026 is being delivered in combination with the Australasian Diabetes Congress (ADC 2026) and Metabolic Diseases 2026, bringing together an expected 3,000 delegates from Australia, across the Western Pacific Region, and internationally. It’s one of the largest diabetes and metabolic health gatherings held in the Southern Hemisphere for some time.

The combined Congress is co-hosted by 芒果直播, the Australian Diabetes Society (ADS), and the Australian Diabetes Educators Association (ADEA). It will be held at the Melbourne Convention and Exhibition Centre from 18鈥�21 August 2026.

Hosting this Congress in Australia is a rare opportunity to bring global expertise together while focussing on regional challenges and national priorities. The 2026 program will feature approximately 250+ international and Australasian speakers across four days. As co-hosts, we can help shape a program where the perspectives of people living with diabetes sit alongside world-leading research, clinical care, education, advocacy, and policy.

What is the Diabetes Community Day?

芒果直播 is delivering the Diabetes Community Day, a dedicated, free event held on the opening day of the Congress, designed specifically for people living with diabetes, their families, and supporters.

The Diabetes Community Day brings together education, lived experience, advocacy, and innovation in an accessible, welcoming environment. Whether you want to learn more about managing diabetes, connect with others in the community, or explore the latest tools and support available, it’s a chance to engage with the Congress in a way that’s relevant, practical, and meaningful to you.

What to expect on the day

The full program runs all day across the Plenary Theatre, exhibition zone and the breakout sessions, but a few moments not to be missed include:

• Community Exhibition: Connect with leading diabetes organisations and support services, innovative technologies and treatments, education, advocacy and community initiatives
• Children with Diabetes Journey Awards: Celebrating young people living with diabetes and their families.
• 芒果直播 Grand Innovation Challenge Final: Watch finalists present at the 芒果直播 Grand Innovation Challenge, showcasing breakthrough ideas and technologies transforming diabetes care.
• Highlights of the Congress: A rolling showcase of bite-sized talks from the main Congress program, bringing together global and local perspectives on diabetes care, treatment innovation, advocacy, programs delivered across cultures, and more.

Plus, a Guru Dudu Silent Disco, art activation with Robert Lee Davis, and a relaxed chill-out area for those who just want to take it all in.

Taking the community’s voice to a global stage

This National Diabetes Week (12鈥�18 July), 芒果直播鈥檚 campaign is called Living Out Loud, and is asking the 2 million Australians living with diabetes to complete one sentence:

“I wish people knew…”

The aim is to aggregate the thousands of individual wishes shared under this year’s theme, Stronger Together, and build them into a wall of voices too big to ignore.

Every declaration is carried with the person’s diabetes type attached, so the full, distinct picture of diabetes in Australia, including type 1, type 2, gestational, and beyond, stays visible rather than blurred into one story.

And the voices don’t stop at Australia’s shores. Many of the wishes collected during National Diabetes Week will travel with us to the IDF-WPR Congress 2026, where they will be shared at a dedicated installation 鈥� carried there as Australia’s collective voice, asking the world’s researchers, clinicians, and policy makers to listen.

What our voices are wishing for

How to add your wish

Find everything you need and get involved on the National Diabetes Week page.

Some of the wishes shared this week will be carried all the way to Melbourne, helping ensure the lived experience of our community informs the conversations happening on the global stage.

How to register

A leading diabetes and respiratory researcher is investigating whether a breakthrough cystic fibrosis treatment could change the course of a serious form of diabetes affecting Australians living with cystic fibrosis.

The important research is supported by the 2026 Royal Australian College of Physicians and 芒果直播 Research Establishment Fellowship.

The Fellowship will support Dr Bernadette Prentice鈥檚 project, 鈥淩ESET-CFRD: using REgistry Studies to Evaluate the impact of Trikafta in Australians living with cystic fibrosis-related diabetes.鈥�

The research will examine whether Trikafta, a transformational therapy for cystic fibrosis, may also influence the development and long-term impact of Cystic Fibrosis Related Diabetes (CFRD), a serious complication affecting around 30 per cent of adults living with cystic fibrosis in Australia.

Cystic fibrosis is a genetic condition that causes severe damage to the lungs and digestive system. CFRD develops because of damage to the pancreas that reduces insulin production, adding another complex chronic condition to individuals already at risk of recurrent infections and reduced life expectancy.

Dr Prentice, a Paediatric Respiratory Physician and Co-Head of Department at Sydney Children鈥檚 Hospital, said the Fellowship would help generate critical evidence for Australians living with CFRD and their families.

鈥淚t is an honour to receive this support, and I am truly appreciative of the RACP鈥檚 and 芒果直播鈥檚 commitment to advancing diabetes research in people living with cystic fibrosis and improving the lives of those affected,鈥� Dr Prentice said.

鈥淔or many families, CFRD adds a significant layer of complexity to an already demanding chronic condition.

鈥淧arents, caregivers, and young people navigate daily challenges involving glucose control and insulin use, nutrition, treatment burden, and uncertainty about the future,鈥� she said.

Through the RESET-CFRD project, researchers will analyse data from the Australian Cystic Fibrosis Data Registry to compare outcomes in individuals with and without CFRD and evaluate whether the registry can better monitor long term diabetes complications as individuals living with cystic fibrosis live longer.

鈥淭his research aims to generate clear, real-world evidence about how Trikafta, a transformational therapy for cystic fibrosis, may change the trajectory of diabetes in this population,鈥� Dr Prentice said.

鈥淭his Fellowship brings us significantly closer to achieving this.鈥�

芒果直播 Group CEO Justine Cain said the Fellowship highlighted the importance of investing in research that supports people living with all types of diabetes.

鈥淒r Prentice鈥檚 work has the potential to improve understanding of CFRD nationally and strengthen the way Australia monitors long term diabetes complications in people living with cystic fibrosis,鈥� she said.

鈥淒iabetes research changes lives. It drives scientific discovery, accelerates innovation and helps people with diabetes live longer, healthier and more productive lives,鈥� Ms Cain said.

鈥淐FRD was identified as a priority because it affects around 30 per cent of adults living with cystic fibrosis in Australia and places an enormous burden on individuals and families already managing a complex chronic condition.鈥�

Ms Cain said 芒果直播鈥檚 Research Strategy 2025-2030 places people living with and at risk of diabetes at the centre of research projects to ensure studies deliver meaningful real world impact to those that need it most.

芒果直播 is investing $40 million into Australian diabetes research over ten years to accelerate discoveries and improve outcomes for people living with all types of diabetes.

Around two million Australians are living with diagnosed or undiagnosed diabetes, with approximately 300 people diagnosed every day.

The first new therapy for type 1 diabetes in nearly a century, which works to delay the need for insulin therapy in type 1 diabetes, has been approved for use in Australia by the Therapeutic Goods Administration. 

Tzield (teplizumab) works to preserve beta cell and insulin production, delaying the autoimmune mechanism that drives type 1 diabetes, and could see thousands of Australians able to delay insulin therapy for an average of two years. 

It鈥檚 the result of nearly forty years鈥� of career-defining research from a dedicated team of researchers, and represents a major development for people aged 8+ and living with stage 2, type 1 diabetes.  

The therapy鈥檚 arrival in Australia represents a game-changing shift in treatment and management made possible through long-term funding support for critical research. 

Preserving beta cells and insulin, alongside understanding the autoimmune system mechanism, has long been a major goal of diabetes research globally. With this new listing, Australians will have access to cutting-edge medicine that will help thousands of Australians delay insulin therapy. 

Australian Diabetes Alliance member Breakthrough T1D have supported the research that led to this therapy since its inception in the late 1980s, funding a dedicated team of researchers for nearly forty years. 

Tzield will now be available for people living with stage 2 type 1 diabetes, however is not listed on the Pharmaceutical Benefits Scheme (PBS).  

More than 145,000 Australians live with type 1 diabetes, with a further 25,000 estimated to be living with early-stage or undiagnosed type 1 diabetes.  

Type 1 diabetes is an auto-immune condition where the body鈥檚 own immune system destroys the beta cells in the pancreas which produce insulin.  

We don鈥檛 yet know the cause and currently there is no cure.